Prof. Shun Lu (陆舜)
MD, PhD — Director of Thoracic Oncology, Shanghai Chest Hospital
Clinical Trial Leadership: Prof. Lu is the principal investigator of the MIZAR-005 Phase Ib/II trial (NCT06473961) evaluating GC101 TIL therapy in advanced NSCLC. The trial is currently activating recruitment at Shanghai Chest Hospital.
Clinical Trial Leadership
Prof. Shun Lu is the principal investigator for the MIZAR-005 GC101 TIL therapy Phase Ib/II clinical trial in advanced non-small cell lung cancer. This study evaluates the safety and efficacy of GC101 in patients who have progressed after platinum-based chemotherapy and anti-PD-1 immunotherapy.
Professional Affiliations
- Director, Department of Thoracic Oncology, Shanghai Chest Hospital
- Executive Board Member, Chinese Society of Clinical Oncology (CSCO)
- Honorary Chairman, Lung Cancer Committee, Chinese Anti-Cancer Association (CACA)
- Chairman, Lung Cancer Expert Committee, Chinese Medical Association
- Principal Investigator, multiple international lung cancer clinical trials
- Published 200+ peer-reviewed articles in oncology journals including JCO, Lancet Oncology, Annals of Oncology
Career & Milestones
MIZAR-005 Trial Activation
Launched the Phase Ib/II trial of GC101 TIL therapy in advanced NSCLC — the first TIL therapy study for lung cancer in China to use a no-lymphodepletion, no-IL-2 regimen.
Lung Cancer Immunotherapy Expertise
Prof. Lu has led numerous Phase I–III clinical trials for novel lung cancer therapies including targeted therapies (EGFR, ALK, ROS1 inhibitors), checkpoint inhibitors, and combination immunotherapies. His team manages one of the largest thoracic oncology patient populations in China.
Research Focus
Prof. Lu's research spans the full spectrum of thoracic malignancies, with a focus on developing novel therapeutic strategies for patients who have progressed on standard treatments. His group has been at the forefront of bringing innovative cell therapies — including TIL therapy — to the lung cancer treatment landscape in China.
External Resources
Frequently Asked Questions About Prof. Shun Lu
Who is Prof. Shun Lu?
Prof. Shun Lu (陆舜) is Director of Thoracic Oncology at Shanghai Chest Hospital, one of China's leading lung cancer specialists. He has published over 200 peer-reviewed articles in journals including JCO, Lancet Oncology, and Annals of Oncology.
What is Prof. Lu's role in the GC101 lung cancer trial?
Prof. Lu is the lead Principal Investigator of MIZAR-005 (NCT06473961), the Phase Ib/II trial of GC101 TIL therapy in advanced NSCLC. The trial uses a no-lymphodepletion, no-IL-2 regimen and targets patients who have failed platinum-based chemotherapy and anti-PD-1 immunotherapy.
What are Prof. Lu's professional affiliations?
Prof. Lu is Executive Board Member of CSCO, Honorary Chairman of the CACA Lung Cancer Committee, and Chairman of the Lung Cancer Expert Committee of the Chinese Medical Association. He has led numerous international lung cancer clinical trials.
How can I be treated by Prof. Lu?
Patients interested in the GC101 NSCLC trial can contact CancerPath at clinicaltrials@juncell.com for a free eligibility assessment. Prof. Lu leads the MIZAR-005 trial at Shanghai Chest Hospital.
Learn About GC101 for Lung Cancer
Read about how TIL therapy works for advanced NSCLC and find out if you may be eligible for the MIZAR-005 trial.
Lung Cancer Treatment Overview →